Basic Calan Sr Information

• INN (International Nonproprietary Name): Verapamil
• Brand Names Available In Canada (English): Calan/Calan SR; Isoptin/Isoptin SR; Tarka (combo with trandolapril); Verelan variants may be available under different suppliers.
• ATC Code: C08DA01
• Forms & Dosages: Immediate-release tablets 40 mg, 80 mg, 120 mg; Extended-release tablets 120 mg, 180 mg, 240 mg; Extended-release capsules 120 mg, 180 mg, 240 mg.
• Manufacturers In Canada (English): Multiple generics supplied by Mylan, Sandoz, Abbott/Knoll and others; Pfizer markets Calan SR in the US; local suppliers vary by province.
• Registration Status In Canada (English): Approved widely by national regulators for hypertension, angina and arrhythmias.
• OTC / Rx Classification: Prescription-only (Rx).

Latest Research Highlights (Canadian + International, 2022–2025)

Clinicians ask whether verapamil still has a clear role for arrhythmias and chronic cardiovascular care.

Recent Canadian cohort analyses (2022–2024) and international randomized controlled trials and meta-analyses indicate verapamil remains effective for supraventricular tachycardia for acute rate control and for long-term management of angina and hypertension as a phenylalkylamine calcium-channel blocker.

Emerging Canadian registry data from 2023–24 emphasise increased monitoring needs for older adults and people on multiple medicines because of higher bradycardia and emergency-department visit signals in polypharmacy cases.

Trials from 2022–24 comparing extended-release (SR/ER) verapamil against diltiazem and amlodipine focused on tolerability and adherence and found sustained-release regimens reduce peak-related adverse events while delivering similar blood-pressure efficacy.

Ongoing 2025 Canadian pharmacovigilance projects are tracking real-world reports of bradycardia and constipation with verapamil use.

Key practice takeaway: many clinicians prefer ER formulations for once-daily dosing in rural and remote care to improve adherence and reduce peak adverse events.

Data Highlights: INN: Verapamil; ATC: C08DA01; Immediate-release 40–120 mg; ER/SR 120–240 mg.

• Top Finding 1: Verapamil remains effective for acute SVT rate control and chronic angina/hypertension management.
• Top Finding 2: ER/SR formulations reduce peak-related adverse events versus immediate release and improve adherence.
• Top Finding 3: Older adults and patients with polypharmacy require closer monitoring due to bradycardia and ED visit signals.

Clinical Effectiveness In Canada (Health Canada Context)

Patients and prescribers want to know if verapamil is approved and how to check product specifics.

Health Canada recognises verapamil formulations for hypertension, angina and certain arrhythmias, consistent with international approvals.

Clinicians should consult the Health Canada product monograph and the specific product monograph identified by the DIN for dosing and contraindication details.

Pharmacies record the Drug Identification Number for reimbursement and pharmacovigilance and use DIN lookups on the Health Canada online database for up-to-date product information.

Health Canada Approval

Prescription-only; approved for hypertension, angina and arrhythmias.

DIN

Provincial coverage and reimbursement hinge on the DIN listed by the product monograph.

SPC (Summary Of Product Characteristics)

Source of dosing details, contraindications and formulation-specific guidance.

• Monitoring Checklist: Heart Rate, Blood Pressure, Constipation, Liver Function Tests for long-term therapy.

Indications & Expanded Uses (Approved Vs Off-Label In Canadian Practice)

People ask what verapamil is officially for and when specialists might use it off-label.

Approved uses include hypertension, chronic stable angina and certain supraventricular arrhythmias such as SVT.

Off-label specialist uses in Canadian practice include specific pediatric arrhythmias on a weight-based specialist regimen and select niche indications such as migraine prophylaxis or hypertrophic cardiomyopathy after multidisciplinary review.

Contraindications are important when considering off-label use; avoid verapamil in advanced heart block or severe heart failure.

Before initiation verify renal and hepatic status and discuss symptom goals such as reduced angina frequency and fewer palpitations.

• Shared Decision Points: Expected benefits, constipation and bradycardia risk, monitoring plan and travel or follow-up logistics for rural patients.

Composition & Brand Landscape (Canada-Focused)

Patients often ask whether brand matters and which brands are common in Canada.

The active ingredient is verapamil hydrochloride (INN: Verapamil).

• Pros/Cons Of Brand Vs Generic: Generics are cost-effective and bioequivalent; brands may be preferred by some patients for familiarity; packaging and blistering options aid seniors.

Pharmacy operations note: bilingual labelling requirements in Canada and differences in packaging across provinces mean pharmacists verify DINs at dispensing for substitutions.

Storage and Administration: Do not crush or chew extended-release forms.

Contraindications & Special Precautions (Canadian At-Risk Groups)

People worry about when verapamil is unsafe.

Absolute contraindications include severe hypotension (systolic under 90 mmHg), advanced second- or third-degree AV block unless a pacemaker is present, sick sinus syndrome unless paced, known hypersensitivity and severe heart failure.

Relative cautions include liver or kidney impairment, older adults who are more sensitive to bradycardia and hypotension, and combination therapy with beta-blockers because of the risk of conduction block.

Absolute Vs Relative Contraindication

Absolute contraindications are conditions where verapamil should not be used; relative contraindications require weighing risks and benefits and closer monitoring.

High-risk monitoring thresholds include heart rate below 50 bpm and symptomatic hypotension.

Cultural and practical aspects: in Indigenous and remote communities where multimorbidity is higher and monitoring access limited, conservative dosing and arranged local nursing follow-up are advised.

• Red Flags Requiring Emergency Department Assessment: Syncope, severe dizziness, chest pain, sudden marked shortness of breath.

Clinical workflow before start: baseline ECG to assess conduction, baseline liver function testing for chronic therapy and a clear patient leaflet with hold criteria.

Dosage Guidelines (Standard Canadian Dosing & Adjustments)

Patients commonly ask how to start verapamil and how dosing differs by formulation.

Immediate-release for angina is typically 80–120 mg three times daily, while extended-release formulations for hypertension or chronic angina are generally 120–240 mg once daily.

Arrhythmia regimens often fall in the 240–320 mg/day divided range depending on the clinical protocol.

Dose adjustments: start lower in older patients and reduce dose in hepatic impairment because verapamil is primarily metabolised in the liver.

Missed Doses: take when remembered unless the next dose is near; do not double doses.

• Monitoring Schedule: baseline BP and HR, reassess 1–2 weeks after initiation or dose change, then every 3–6 months if stable.

Peri-procedural use such as intravenous regimens for cardioversion require inpatient protocols and are beyond outpatient dosing tables.

Interactions Overview (Drugs, Food, Lifestyle Common In Canada)

Patients should know what not to mix with verapamil.

Major interactions include strong CYP3A4 inhibitors and inducers which can alter verapamil plasma levels, and co-administration with beta-blockers which increases the risk of bradycardia and AV block.

Digoxin levels may rise when combined with verapamil and require monitoring.

Grapefruit and grapefruit juice can increase verapamil exposure and should be avoided.

Data highlights show many emergency-department visits with verapamil relate to symptomatic bradycardia in elderly patients taking additional rate-slowing drugs.

• Pharmacy Practice Tip: Use electronic interaction checks and provincial eMed tools and provide bilingual counselling for francophone patients.

Cultural Perceptions & Patient Habits (Canadian Patient Voice)

Patients commonly report constipation and tiredness as the most bothersome side effects when taking verapamil.

Online patient groups and forums in Canada mention constipation and fatigue as primary adherence barriers.

Francophone patients in Quebec often request French information leaflets and Indigenous patients may prioritise minimizing travel and clinic visits for monitoring.

Urban patients generally have easier access to retail pharmacy chains such as Shoppers Drug Mart, Rexall and London Drugs, whereas rural patients often use postal pharmacies or nurse-led clinics.

• Common Patient Concerns: Cost, side effects like constipation, logistics of follow-up and coverage under provincial plans.

Practical adherence aids include blister packs, once-daily ER formulations and pharmacist-led medication reviews to address side effects and interactions.

Side effects to counsel on: constipation, dizziness, ankle edema and bradycardia.

Availability & Pricing Patterns (Canadian Pharmacies & Cross-Border Notes)

Canadians ask where to buy verapamil and how much it costs.

Verapamil is a prescription-only medicine in Canada.

Major chains that commonly stock verapamil and generics include Shoppers Drug Mart, Rexall, Jean Coutu and London Drugs, and wholesalers such as Sandoz and Mylan supply most generics.

Steps For Lower Cost: ask pharmacist for a generic equivalent, check provincial programs, or seek patient-assistance programs where available.

Note: our online pharmacy offers calan sr with discreet delivery across Canada in 5–14 days.

Comparable Medicines And Preferences (Alternatives In Canada)

Many clinicians consider alternatives depending on indication and comorbidity.

• Pros/Cons Checklist: Verapamil provides strong AV-node rate control useful in SVT but commonly causes constipation; amlodipine is potent for vasodilation but causes ankle edema; diltiazem offers intermediate rate control and vasodilation.

Decision factors in Canada include comorbid respiratory disease, formulary preferences, and patient-reported tolerance of side effects.

Local cardiology guidance is recommended for atrial fibrillation rate control or complex cases where guideline choice varies between verapamil, diltiazem and beta-blockers.

FAQ Section

Q: Can I get Calan SR without a prescription?

A: No — verapamil is a prescription-only medicine in Canada; consult a prescriber for a valid prescription.

Q: Is generic verapamil as good as Calan SR?

A: Generics are bioequivalent and widely used; check the DIN and provincial rules for pharmacist substitution and coverage.

Q: What should I do about constipation while on verapamil?

A: Increase fibre and fluids, stay active and discuss stool softeners or laxatives with a pharmacist if lifestyle measures are insufficient.

Q: Can I drink grapefruit juice while taking verapamil?

A: Avoid grapefruit juice because it can increase verapamil levels and raise the chance of side effects like dizziness and bradycardia.

Q: What if I miss a dose?

A: Take as soon as you remember unless it is close to the next dose; never double the next dose.

• When To Seek Emergency Care: chest pain, fainting, severe dizziness, signs of very low blood pressure or very slow heart rate.

Referral Note: For coverage questions consult Ontario Drug Benefit, BC PharmaCare or RAMQ and visit your community pharmacy for DIN and prior-authorization assistance.

Guidelines For Proper Use (Pharmacist-Led Counselling & Provincial Tips)

Pharmacists frequently lead initial counselling and follow-up for verapamil starts.

Confirm indication, current medicines, allergies, pregnancy and breastfeeding status, baseline heart rate and blood pressure and liver function tests before dispensing.

Counsel: do not crush or chew extended-release tablets, take ER formulations at the same time every day and avoid grapefruit products.

• Pharmacist Checklist For Dispensing: Verify DIN and formulary status, provide bilingual patient information, counsel on side effects and interactions, offer blister packs and schedule a medication review.

Provincial Tips: check ODB, PharmaCare and RAMQ criteria for coverage and document substitutions in dispensing records as required.

Rural And Remote Tip: arrange nurse follow-up or virtual BP and HR checks and provide an extra supply when travel or postal delays are likely.

Emergency Advice: urgent ED referral for severe hypotension, syncope or chest pain.

Follow-Up Schedule: review at 1–2 weeks after initiation or dose change and then quarterly if stable.

Delivery Across Canada (English)